1. Show article details.

    BRIEF-Berkshire Hathaway Dissolves Share Stake In Abbvie, Bristol-Myers; Takes Share Stake in Paramount Global, Ally Financial

    Reuters – 6:02 PM ET 05/16/2022

    BERKSHIRE HATHAWAY (BRK/A): * BERKSHIRE HATHAWAY DISSOLVES SHARE STAKE IN ABBVIE - SEC FILING. * BERKSHIRE HATHAWAY TAKES SHARE STAKE IN ALLY FINANCIAL - SEC FILING. * BERKSHIRE HATHAWAY TAKES SHARE STAKE IN PARAMOUNT GLOBAL - SEC FILING. * BERKSHIRE HATHAWAY DISSOLVES SHARE STAKE IN BRISTOL-MYERS SQUIBB - SEC FILING.

  2. Show article details.

    AbbVie, Cugene Ink Licensing Pact For Autoimmune & Inflammatory Disease Candidate

    Benzinga – 12:27 PM ET 05/16/2022

    AbbVie, Cugene Ink Licensing Pact For Autoimmune & Inflammatory Disease Candidate

  3. Show article details.

    AbbVie to Showcase Depth of Gastroenterology Portfolio and Pipeline at Digestive Disease Week®

    PR Newswire – 8:00 AM ET 05/16/2022

    NORTH CHICAGO, Ill. AbbVie's (ABBV) research to be presented at DDW 2022 addresses digestive and inflammatory bowel diseases, including ulcerative colitis, Crohn's disease, and irritable bowel syndrome with constipation / chronic idiopathic constipation.

  4. Show article details.

    BRIEF-Abbvie And Cugene Announce Collaboration In Autoimmune Diseases

    Reuters – 7:40 AM ET 05/16/2022

    Abbvie Inc (ABBV): * ABBVIE AND CUGENE ANNOUNCE COLLABORATION IN AUTOIMMUNE DISEASES. * Abbvie Inc (ABBV) - RECEIVES OPTION TO LICENSE WORLDWIDE RIGHTS TO CUG252 FROM CUGENE.

  5. Show article details.

    AbbVie and Cugene Announce Collaboration in Autoimmune Diseases

    PR Newswire – 7:30 AM ET 05/16/2022

    - AbbVie (ABBV) receives the option to license worldwide rights to CUG252 from Cugene, a clinical-stage and potential best-in-class Treg-selective IL-2 mutein, building on AbbVie's (ABBV) commitment to developing novel therapies in immunology - Cugene to complete a Phase 1a study in healthy volunteers and to conduct a Phase 1b study in patients with autoimmune/inflammatory disease during the option period ...

  6. Show article details.

    Japan pharma lobbies say pricing scheme leading to renewed 'drug lag'

    Reuters – 3:24 AM ET 05/16/2022

    Japan's three major pharmaceutical lobbies joined for the first time on Monday in urging reforms to the government's drug-pricing system to avoid losing out on investment and new drugs.

  7. Show article details.

    ABBV DEADLINE: Kessler Topaz Meltzer & Check, LLP Reminds Investors of AbbVie, Inc. of Deadline in Securities Fraud Class Action Lawsuit and Encourages Investors with Substantial Losses to Contact the Firm

    PR Newswire – 12:12 PM ET 05/14/2022

    RADNOR, Pa. , May 14, 2022 The law firm of Kessler Topaz Meltzer & Check, LLP  informs investors that the firm has filed a securities class action lawsuit against AbbVie, Inc. (ABBV) on behalf of all persons and entities who purchased or otherwise acquired AbbVie (ABBV) securities between April 30, 2021, and August 31, 2021, inclusive. CLICK HERE TO SUBMIT YOUR ABBVIE LOSSES.

  8. Show article details.

    Kessler Topaz Meltzer & Check, LLP Reminds AbbVie, Inc. Investors of Deadline in Securities Fraud Class Action Lawsuit

    GlobeNewswire – 1:49 PM ET 05/12/2022

    The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that the firm has filed a securities class action lawsuit in the United States District Court for the Northern District of Illinois against AbbVie, Inc. (ABBV) on behalf of all persons and entities who purchased or otherwise acquired AbbVie (ABBV) securities between April 30, 2021, and August 31, 2021, inclusive.

  9. Show article details.

    AbbVie to Showcase Oncology Portfolio and Pipeline During the 2022 ASCO and EHA Annual Congresses

    PR Newswire – 11:39 AM ET 05/12/2022

    NORTH CHICAGO, Ill. "AbbVie (ABBV) continues working to transform the standards of care for cancer treatments as a result of our commitment to patients, innovation and partnerships," said Mohamed Zaki, M.D., Ph.D., vice president and global head of oncology development, AbbVie.

  10. Show article details.

    Genmab Announces Multiple Abstracts to Be Presented at the European Hematology Association (EHA) Annual Congress

    Business Wire – 10:00 AM ET 05/12/2022

    COPENHAGEN, Denmark---- Genmab A/S (GMAB) announced today that multiple abstracts evaluating epcoritamab, an investigational subcutaneous bispecific antibody, will be presented at the European Hematology Association Annual Congress, being held in Vienna, Austria, and virtually, June 9-12.

  11. Show article details.

    AbbVie Awards 45 Scholarships to U.S. Students Living with Chronic, Immune-Mediated Diseases in Their Pursuit of Higher Education

    PR Newswire – 8:30 AM ET 05/12/2022

    Since 2016, the AbbVie Immunology Scholarship program has helped more than 300 students impacted by immune-mediated diseases across rheumatology, gastroenterology and dermatology NORTH CHICAGO, Ill.

  12. Show article details.

    ABBV LAWSUIT ALERT: Levi & Korsinsky Notifies AbbVie Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

    PR Newswire – 5:45 AM ET 05/12/2022

    NEW YORK, May 12, 2022 Levi & Korsinsky, LLP notifies investors in AbbVie Inc. (ABBV) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of AbbVie (ABBV) investors who were adversely affected by alleged securities fraud between April 30, 2021 and August 31, 2021.

  13. Show article details.

    AbbVie's Upadacitinib Shows Clinical Response In Crohn's Disease Maintenance Study At One Year

    Benzinga – 11:41 AM ET 05/11/2022

    AbbVie's Upadacitinib Shows Clinical Response In Crohn's Disease Maintenance Study At One Year

  14. Show article details.

    Teva, Allergan Ready To Pay $5B To Settle Lawsuits Related To Opioid Painkillers: Bloomberg

    Benzinga – 8:51 AM ET 05/11/2022

    Teva, Allergan Ready To Pay $5B To Settle Lawsuits Related To Opioid Painkillers: Bloomberg

  15. Show article details.

    BRIEF-Abbvie Inc - Upadacitinib (RINVOQ®) Achieved Clinical Remission And Endoscopic Response At One Year In Phase 3 Maintenance Study In Patients With Crohn's Disease

    Reuters – 8:50 AM ET 05/11/2022

    Abbvie Inc (ABBV): * Abbvie Inc (ABBV) - UPADACITINIB ACHIEVED CLINICAL REMISSION AND ENDOSCOPIC RESPONSE AT ONE YEAR IN PHASE 3 MAINTENANCE STUDY IN PATIENTS WITH CROHN'S DISEASE. * Abbvie Inc (ABBV) - SAFETY RESULTS IN STUDY WERE GENERALLY CONSISTENT WITH KNOWN PROFILE OF UPADACITINIB, WITH NO NEW SAFETY RISKS OBSERVED.

  16. Show article details.

    Upadacitinib (RINVOQ®) Achieved Clinical Remission and Endoscopic Response at One Year in Phase 3 Maintenance Study in Patients with Crohn's Disease

    PR Newswire – 8:45 AM ET 05/11/2022

    NORTH CHICAGO, Ill. In the U-ENDURE maintenance study, patients from U-EXCEED and U-EXCEL who responded to 12 weeks of upadacitinib 45 mg oral induction treatment were re-randomized to receive upadacitinib 15 mg, upadacitinib 30 mg, or placebo.

  17. Show article details.

    Walgreens, CVS, Walmart begin $878 million opioid trial in Ohio

    Reuters – 6:00 AM ET 05/10/2022

    CVS Health Corp (CVS), Walgreens Boots Alliance Inc (WBA) and Walmart Inc (WMT) on Tuesday begin a first-of-its-kind trial to determine what the pharmacy chains owe for their role in the opioid epidemic in two Ohio counties, which are seeking $878 million.

  18. Show article details.

    7 Stocks Moved By Traders On 'Fast Money: Halftime Report'

    Benzinga – 1:49 PM ET 05/05/2022

    CNBC's "Fast Money: Halftime Report" delivers market-moving news to investors. The commentary delivered by hosts of the show often moves the stocks mentioned. Charter Communications Inc 12:47 P.M. - Sarat Sethi of DCLA said he purchased more of Charter's stock, shares initially climbed 0.53% before slipping 0.17% lower.

  19. Show article details.

    Walgreens reaches $683 mln opioid settlement with Florida

    Reuters – 9:06 AM ET 05/05/2022

    Walgreens Boots Alliance (WBA) said on Thursday it has reached a $683 million settlement with Florida to resolve claims that the pharmacy chain exacerbated an opioid epidemic in the state. The settlement includes $620 million to be paid to Florida over 18 years, plus $63 million for legal fees.

  20. Show article details.

    ABBV LAWSUIT ALERT: Levi & Korsinsky Notifies AbbVie Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

    PR Newswire – 5:45 AM ET 05/05/2022

    NEW YORK, May 5, 2022 Levi & Korsinsky, LLP notifies investors in AbbVie Inc. (ABBV) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of AbbVie (ABBV) investors who were adversely affected by alleged securities fraud between April 30, 2021 and August 31, 2021.

Page:

Today's and Upcoming Events

  • Jul
    28

    ABBV to announce Q2 earnings (Unconfirmed)

  • Jul
    14

    ABBV ex-Dividend for $1.41 on 07/14/2022

    • Announce Date: 06/23/2022
    • Record Date: 07/15/2022
    • Pay Date: 08/15/2022

Past Events (last 90 days)

  • Apr
    29

    ABBV announced Q1 earnings.

  • Apr
    13

    ABBV ex-Dividend for $1.41 on 04/13/2022

    • Announce Date: 02/17/2022
    • Record Date: 04/15/2022
    • Pay Date: 05/16/2022
Data provided by Thomson Reuters © 2022

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.